Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017” research report to their offering. See more at: http://mrr.cm/ZU2

1. www.MarketResearchReports.com
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: March 27, 2014
 Number of Pages: 179
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 5,995
Price For Site User License: USD 11,990
Price For Global User License: USD 17,985
Delivery Time: Within 24 Hours (During Working Days)

3. www.MarketResearchReports.com
About the Report
OpportunityAnalyzer: Pancreatic Cancer Opportunity
Analysis and Forecasts to 2017 report focuses on the
current treatment landscape, unmet needs, pipeline and
commercial opportunity in the pancreatic cancer market
with coverage of both the early stage resectable and
advanced settings. Celgene’s Abraxane was launched in
the US and Europe in 2013 and 2014, respectively, and
was the first drug approved in this disease in nearly a
decade.
Due to the high unmet need, Publisher forecasts the rapid
uptake of Abraxane, and sales of this drug are expected to
drive the overall pancreatic cancer market and are
forecast to represent greater than 50% of total market
sales in 2017.

4. www.MarketResearchReports.com
Research Findings
Publisher estimates that the value of the pancreatic cancer
market in the US and 5EU (France, Germany, Italy, Spain, and the
UK) in 2012 was $529m. This market is defined as sales of
branded drugs and major generic regimens commonly
prescribed for pancreatic cancer patients across the six major
markets (6MM). Just over half of these sales, $275m (52%), were
generated in the US, while sales in the 5EU were estimated at
$254m (48%).
By 2017, the end of the forecast period, Publisher projects
pancreatic cancer sales to rise to $1.63 billion in the US and 5EU,
at a high Compound Annual Growth Rate (CAGR) of 25.2%.
Publisher expects the proportion of sales from the US to
increase to 72%, with market share in the 5EU decreasing to 28%
by 2017.
Publisher forecasts sales of Abraxane to rise significantly, from
$21m in 2012 to $954m in 2017, at a CAGR of 115%; sales of
Abraxane will represent nearly 60% of the pancreatic cancer
market by the end of the forecast period

5. www.MarketResearchReports.com
Scope
Overview of pancreatic cancer, including epidemiology,
etiology, pathophysiology, symptoms, prognosis, and
clinical staging.
Topline pancreatic cancer therapeutics market revenue
from 2012–2017. Annual cost of therapy, and major
marketed and pipeline drug sales in this forecast period
are included.
Key topics covered include strategic competitor
assessment, market characterization, unmet needs, R&D
strategies, and clinical trial design for the pancreatic
cancer therapeutics market.

6. www.MarketResearchReports.com
Scope Continues…
Pipeline analysis: comprehensive data split across
different phases, emerging novel trends under
development, synopses of innovative early-stage
projects, and detailed analysis of late-stage pipeline
drugs. An interactive clinical and commercial analyzer tool
is available.
Analysis of the current and future market competition in
the 6MM pancreatic cancer therapeutics market.
Insightful review of the key industry drivers, restraints
and challenges. Each trend is independently researched to
provide qualitative analysis of its implications.

7. www.MarketResearchReports.com
Reasons To Buy
Develop and design your in-licensing and out-licensing
strategies through a review of pipeline products and
technologies, and by identifying the companies with the most
robust pipeline.
Develop business strategies by understanding the trends
shaping and driving the 6MM pancreatic cancer market.
Drive revenues by understanding the key trends, innovative
products and technologies, market segments, and companies
likely to impact the 6MM pancreatic cancer therapeutics market
in the future.
Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analysing the
performance of various competitors.
Identify emerging players with potentially strong product
portfolios and create effective counter-strategies to gain a
competitive advantage.

8. www.MarketResearchReports.com
Report Coverage
Table of Contents
Introduction
Disease Overview
Epidemiology
Current Treatment Options
Unmet Needs Assessment and Opportunity
Analysis
Research and Development Strategies
Pipeline Assessment
Pipeline Valuation Analysis
Appendix

9. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center

10. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/ZU2
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)